HIV And HCV adherence and treatment outcomes among people who inject drugs receiving opioid agonist therapy.
HIV And HCV adherence and treatment outcomes among people who inject drugs receiving opioid agonist therapy.
复制标题
DOI：
10.1080/09540121.2021.1973659
复制
发表时间：
2022-10
期刊：
影响因子：
1.7
通讯作者：
Litwin AH
中科院分区：
文献类型：
--
作者：
J Minhas H;Akiyama MJ;Norton BL;Heo M;Arnsten JH;Litwin AH
在注射吸毒者(PWID)中，60%的人感染了丙型肝炎病毒，50%-90%的艾滋病毒感染者同时感染了丙型肝炎病毒。比较丙型肝炎病毒单一感染和HIV/丙型肝炎病毒混合感染PWID患者对直接作用抗病毒(DAA)治疗的依从性的数据有限。丙型肝炎病毒治疗开始对HIV抗逆转录病毒治疗(ART)依从性的影响也鲜为人知。我们评估了单独感染丙型肝炎病毒和HIV/丙型肝炎病毒混合感染的PWID患者的DAA依从性，并检查了丙型肝炎病毒治疗后ART依从性和HIV结局的变化。这项研究是在纽约布朗克斯的三个阿片使用障碍(Moud)药物治疗计划中进行的，使用电子泡罩包装来衡量丙型肝炎病毒治疗的依从性。比较和控制过去30天内研究臂、精神疾病和酒精中毒的2周DAA依从率。使用参与者自我报告来衡量ART依从性，并将其分为“优秀”或“一般”。在丙型肝炎治疗前6个月、治疗期间和治疗后6个月分别检测抗逆转录病毒治疗依从性、CD4计数和HIV病毒载量。统计学意义用混合效应回归线性模型或Logistic模型进行评估。丙型肝炎病毒单一感染者和HIV/丙型肝炎病毒/丙型肝炎病毒混合感染者的总体DAA依从率分别为74%(95%CI=71-78%)和76%(95%CI=70-83%)(p=.55)。在丙型肝炎治疗前、治疗期间或治疗后，抗逆转录病毒治疗依从性、CD4计数或HIV病毒载量没有显著变化。这是第一项评估DAA疗法对PWID患者的抗逆转录病毒治疗依从性和HIV治疗结果的影响的研究。这是第一个比较丙型肝炎病毒和HIV/丙型肝炎病毒混合感染的PWID患者对DAA依从性的研究之一。我们的数据显示，DAA依从性没有显著差异，丙型肝炎病毒治疗对ART依从性或HIV结局也没有显著影响。
Among people who inject drugs (PWID), 60% have HCV and 50–90% of HIV-infected PWID are co-infected with HCV. Data comparing adherence to direct acting antiviral (DAA) therapy among HCV mono-infected and HIV/HCV co-infected PWID is limited. The impact of HCV treatment initiation on HIV antiretroviral therapy (ART) adherence is also poorly understood. We assessed DAA adherence in HCV mono-infected and HIV/HCV co-infected PWID and examined changes in ART adherence and HIV outcomes following HCV treatment. Study was conducted in three Medication for Opioid use Disorder (MOUD) programs in Bronx, New York HCV treatment adherence was measured using electronic blister packs. 2-week DAA adherence rates were compared and controlled for study arm, psychiatric illness and alcohol intoxication within the past 30 days. ART adherence was measured using participant self-report and dichotomized to “excellent” or “other.” ART adherence, CD4 count, and HIV viral load were identified 6-months prior to, during, and 6-months after HCV treatment. Statistical significance was assessed with mixed-effects regression linear or logistic models. Overall DAA adherence rates among HCV mono-infected and HIV/HCV co-infected PWID were 74% (95% CI=71–78%) and 76% (95%CI=70–83%), respectively (p=.55). There were no significant changes in ART adherence, CD4 counts, or HIV viral loads prior to, during, or after HCV treatment. This is the first study assessing the impact of DAA therapy on ART adherence and HIV treatment outcomes among PWID. It is one of the first to compare DAA adherence among HCV and HIV/HCV co-infected PWID. Our data demonstrate no significant difference in DAA adherence and no significant impact of HCV treatment on ART adherence or HIV outcomes.
登录
查看更多内容
DOI：
10.1111/j.1478-3231.2011.02706.x
发表时间：
2012-02
期刊：
Liver international : official journal of the International Association for the Study of the Liver
影响因子：
--
作者：
McGowan CE;Fried MW
通讯作者：
Fried MW
HIV共同感染对使用Ledipasvir和Sofosbuvir的丙型肝炎病毒治疗的12周疗法的影响。
DOI：
10.1097/qad.0000000000000903
发表时间：
2016-01
期刊：
AIDS (London, England)
影响因子：
--
作者：
通讯作者：
--
影响因子：
3.6
作者：
Axley P;Ahmed Z;Ravi S;Singal AK
通讯作者：
Singal AK
影响因子：
2.7
作者：
Myles, Angelique;Mugford, Gerry J.;Wang, Peizhong Peter
通讯作者：
Wang, Peizhong Peter
DOI：
10.1056/nejmoa1501315
发表时间：
2015-08-20
期刊：
The New England journal of medicine
影响因子：
--
作者：
Naggie S;Cooper C;Saag M;Workowski K;Ruane P;Towner WJ;Marks K;Luetkemeyer A;Baden RP;Sax PE;Gane E;Santana-Bagur J;Stamm LM;Yang JC;German P;Dvory-Sobol H;Ni L;Pang PS;McHutchison JG;Stedman CA;Morales-Ramirez JO;Bräu N;Jayaweera D;Colson AE;Tebas P;Wong DK;Dieterich D;Sulkowski M;ION-4 Investigators
通讯作者：
ION-4 Investigators